A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer

A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer is a phase 3 interventional study registered as NCT07673887, led by Astellas Pharma Global Development, and recruiting on the registry. Official title: A Phase 3, Global, Multi-centre, Double-blind, Randomised Study of ASP2138 Plus Chemotherapy (CAPOX or mFOLFOX6) With Pembrolizumab vs Placebo Plus Chemotherapy With or Without Pembrolizumab in First-line Treatment of Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma in Participants Whose Tumours Are HER2-negative and Claudin (CLDN) 18.2-positive. Planned enrolment is 570 participants (estimated). The study started in 2026-06-30 and primary completion is expected in 2031-02-28. No results have been posted on ClinicalTrials.gov.